Advertisement

Human Trials of Endocrine Management

  • Daniel P. de Klerk

Abstract

Benign prostatic hyperplasia (BPH) may be the most common neoplastic disease in man. The increased incidence of BPH with age is well established.23 The initiation of the disease process probably occurs prior to 40 years of age,39 although the clinical manifestations of the disease may become apprarent only with advancing years.

Keywords

Benign Prostatic Hyperplasia Benign Prostatic Hypertrophy Cyproterone Acetate Prostatic Size Prostatic Urethra 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andersen JT, Jacobsen O, Strandgaard L: The diagnostic value of intravenous pyelography in infravesical obstruction in males. Scand J Urol Nephrol 11: 225–230, 1977PubMedCrossRefGoogle Scholar
  2. 2.
    Bartsch G, Frick J, Riiegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP: Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122: 481–486, 1979PubMedGoogle Scholar
  3. 3.
    Bartsch G, Miiller HR, Oberholzer M, Rohr HP: Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122: 487–491, 1979PubMedGoogle Scholar
  4. 4.
    Birkhoff JD, Wiederhorn AR, Hamilton ML, Zinsser HH: Natural history of benign prostatic hypertrophy and acute urinary retention. Urology 7: 48–52, 1976PubMedCrossRefGoogle Scholar
  5. 5.
    Bissada NK, Finkbeiner AE, Redman JF: Accu-racy of preoperative estimation of resection weight in transurethral prostatectomy. J Urol 116: 201–202, 1976PubMedGoogle Scholar
  6. 6.
    Bolton NJ, Lahtonen R, Hammond GC, Vihko R: Distribution and concentration of androgens in epithelial and stromal compartments of the human benign hypertrophic prostate. J Endocrinol 90: 125–131, 1981PubMedCrossRefGoogle Scholar
  7. 7.
    Brown M, Wickam JEA: The urethral pressure profile. Br J Urol 41: 211–217, 1969PubMedCrossRefGoogle Scholar
  8. 8.
    Cabot AT: The question of castration for enlarged prostate. Am Surg 24: 265–309, 1896Google Scholar
  9. 9.
    Caine M, Perlberg S, Gordon R: The treatment of benign prostatic hypertrophy with flutamide (SCH 13521) a placebo-controlled study. J Urol 114: 564–568, 1975PubMedGoogle Scholar
  10. 10.
    Caine M, Pfau A, Perlberg S: The use of alpha adrenergic blockers in benign prostatic hyperplasia. Br J Urol 48: 255–263, 1976PubMedGoogle Scholar
  11. 11.
    Castro JE, Griffiths HJL, Edwards DW: A double- blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Br J Surg 58: 485–489, 1971PubMedCrossRefGoogle Scholar
  12. 12.
    Castro JE, Griffiths HJL, Shackman R: Significance of signs and symptoms in benign prostatic hypertrophy. Br Med J 2: 598–601, 1969PubMedCrossRefGoogle Scholar
  13. 13.
    Clarke R: The prostate and the endocrines: a control series. Br J Urol 9: 254–271, 1937CrossRefGoogle Scholar
  14. 14.
    Coffey DS, de Klerk DP, Walsh PC: Benign prostatic hyperplasia: current concepts. In James VHT (ed.): Proceedings of the V International Congress of Endocrinology, Hamburg. Excerpta Medica International Congress Series No. 403, 1976, pp 495–499Google Scholar
  15. 15.
    Cowan RA, Cowan SK, Grand JK, Elder HY: Biochemical investigations of separated epithelium and stroma from benign hyperplastic prostatic tissue. J Endocrinol 74: 111–120, 1977PubMedCrossRefGoogle Scholar
  16. 16.
    Cuhna GR: Tissue interactions between epithelium and mesenchyme of urogenital and integumental origin. Anat Rec 172: 529–541, 1972CrossRefGoogle Scholar
  17. 17.
    David A, Edwards K, Fellowes KP, Plummer JM: Antiovulatory and other biological properties of megesterol acetate. J Reprod Fertil 5: 331–346, 1963CrossRefGoogle Scholar
  18. 18.
    De Klerk DP, Coffey DS: Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique, biomorphometrics. Invest Urol 16: 240–246, 1978Google Scholar
  19. 19.
    Deming CL, Jenkins RH, Van Wagenen P: Some endocrinological relationships of prostatic hypertrophy: clinical and experimental studies; preliminary report. J Urol 33: 388–399, 1935Google Scholar
  20. 20.
    Donkervoort T, Sterling AM, Van Ness J, Zinner NR, Donker PJ, Ritter RC: Megesterol acetate in treatment of benign prostatic hyperplasia. Urology 6: 580–587, 1975PubMedCrossRefGoogle Scholar
  21. 21.
    Fang S, Liao S: Antagonistic action of antiandrogens on the formation of a specific dihydrotestosterone-receptor-protein complex in the rat ventral prostate. Mol Pharmacol 5: 420–431, 1969Google Scholar
  22. 22.
    Farrar DJ, Pryor JS: The effect of bromocryptine in patients with benign prostatic hypertrophy. Br J Urol 48: 73–75, 1976PubMedCrossRefGoogle Scholar
  23. 23.
    Franks LM: Benign nodular hyperplasia of the prostate—a review. Ann R Coll Surg Engl 14: 92–105, 1954Google Scholar
  24. 24.
    Franks LM, Riddle PN, Carbonell AW, Gey GO: Comparative study of the ultrastructure and lack of growth capacity of adult human prostate epithelium mechanically separated from its stroma. J Pathol 100: 113–119, 1970PubMedCrossRefGoogle Scholar
  25. 25.
    Geller J, Adler EH, Albert J, Brown DW, Licudan A, Manaig E: Using antiandrogen therapy in benign prostatic hyperplasia. Geriatrics 32: 63–71, 1977PubMedGoogle Scholar
  26. 26.
    Geller J, Albert J, Geller S, Lopez D, Cantor T, Yen S: Effect of megesterol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. J Clin Endocrinol Metab 43: 1000–1008, 1976PubMedCrossRefGoogle Scholar
  27. 27.
    Geller J, Angrist A, Nakao K, Newman H: Therapy with progestational agents in advanced benign prostatic hypertrophy. JAMA 210: 1421–1427, 1969PubMedCrossRefGoogle Scholar
  28. 28.
    Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R: Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate. JAMA 193: 115–122, 1965Google Scholar
  29. 29.
    Gordon HW, Schaffner CP: The effect of polyene macrolides on the prostate gland and canine prostatic hypertrophy. Proc Natl Acad Sci USA 60: 1201–1208, 1968PubMedCrossRefGoogle Scholar
  30. 30.
    Hall DA: Gerontology: collagen disease. J Clin Endocrinol Metab 10: 23–55, 1981CrossRefGoogle Scholar
  31. 31.
    Henneberry M, Carter MF, Neiman HL: Estimation of prostatic size by suprapubic ultrasonography. J Urol 121: 615–616, 1979PubMedGoogle Scholar
  32. 32.
    Hodgson BJ, Dumas J, Boiling DR, Heesch CM: Effect of estrogen on sensitivity of rabbit bladder and urethra to phenylephrine. Invest Urol 16: 67–69, 1978PubMedGoogle Scholar
  33. 33.
    Huggins C, Stevens RA: The effect of castration on benign hypertrophy of the prostate in man. J Urol 43: 705–714, 1940Google Scholar
  34. 34.
    Kaufman JJ, Goodwin WE: Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy. J Urol 81: 165–171, 1959PubMedGoogle Scholar
  35. 35.
    Keshin JG: Effect of candicidin on the human benign hypertrophied prostate gland. Int Surg 58: 116–122, 1973PubMedGoogle Scholar
  36. 36.
    Kriek JA, Van der Walt BJ, Bester AJ: Isolation and characterization of adult bovine heart muscle chalones. Proc Natl Acad Sci USA 78: 4161–4164, 1981PubMedCrossRefGoogle Scholar
  37. 37.
    Liao S, Howell DK, Chang T: Action of a nonsteroidal anti-androgen, flutamide on the receptor binding and nuclear retention of 5α-dihydrotestosterone in rat ventral prostate. Endocrinology 94: 1206–1214, 1974CrossRefGoogle Scholar
  38. 38.
    Mariotti A, Thornton M, Mawhinney M: Actions of androgen and estrogen on collagen levels in male accessory sex organs. Endocrinology 109: 837–843, 1981PubMedCrossRefGoogle Scholar
  39. 39.
    McNeal JE: Origin and evolution of benign prostatic enlargement. Invest Urol 15: 340–345, 1978PubMedGoogle Scholar
  40. 40.
    Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J: Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate. Urology 9: 144–148, 1977PubMedCrossRefGoogle Scholar
  41. 41.
    Meyhoff HH, Hald T: Are doctors able to assess prostatic size? Scand J Urol Nephrol 12: 219–221, 1978PubMedCrossRefGoogle Scholar
  42. 42.
    Meyhoff HH, Ingemann L, Nordling J, Hald T: Accuracy in pre-operative estimation of prostatic size. Scand J Urol Nephrol 15: 45–51, 1981PubMedCrossRefGoogle Scholar
  43. 43.
    Muntzing J, Liljekwist J, Murphy GP: Chalones and stroma as possible growth-limiting factors in the rat ventral prostate. Invest Urol 16: 399–402, 1979PubMedGoogle Scholar
  44. 44.
    Neri R, Florance K, Koziol P, Van Cleave S: A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4-nitro-3-trifluoromethyl-isobutyroni- lide). Endocrinology 91: 427–437, 1972PubMedCrossRefGoogle Scholar
  45. 45.
    Neri RO, Monahan M: Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia. Invest Urol 10: 123–130, 1972PubMedGoogle Scholar
  46. 46.
    Neri RO, Monahan MD, Meyer JG, Afonso BA, Tabachnick IA: Biological studies on an antiandrogen (SH 714). Eur J Pharmacol 1: 438–444, 1967PubMedCrossRefGoogle Scholar
  47. 47.
    Paulson DF, Kane RD: Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. J Urol 113: 811–815, 1975PubMedGoogle Scholar
  48. 48.
    Pradhan BK, Chandra K: Morphogenesis of nodular hyperplasia prostate. J Urol 113: 210–213, 1975PubMedGoogle Scholar
  49. 49.
    Rajalakshmi N, Prasad MRN: Metabolism of testosterone by the epididymis and ventral prostate of rat and its inhibition by cyproterone acetate. Steroids 28: 143–157, 1976PubMedCrossRefGoogle Scholar
  50. 50.
    Rangno RE, McLeod PJ, Ruedy J, Ogilvie RI: Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther 12: 658–665, 1971PubMedGoogle Scholar
  51. 51.
    Raz S, Zeigler M, Caine M: Hormonal influences on the adrenergic receptors of the ureter. Br J Urol 44: 405–411, 1972PubMedCrossRefGoogle Scholar
  52. 52.
    Raz S, Zeigler M, Caine M: Pharmacological receptors in the prostate. Br J Urol 45: 663–667, 1973PubMedCrossRefGoogle Scholar
  53. 53.
    Scott WW: What makes the prostate grow? J Urol 70: 477–488, 1953PubMedGoogle Scholar
  54. 54.
    Scott WW, Coffey DS: Nonsurgical treatment of human benign prostatic hyperplasia. Vitam Horm 33: 439–465, 1975PubMedCrossRefGoogle Scholar
  55. 55.
    Scott WW, Wade JC: Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 101: 81–85, 1969PubMedGoogle Scholar
  56. 56.
    Sporer A, Cohen S, Kamat MH, Seebode JJ: Candicidin: physiologic effect on the prostate. Urology 6: 298–303, 1975PubMedCrossRefGoogle Scholar
  57. 57.
    Sufrin G, Coffey DS: A new model for studying the effect of drugs on prostatic growth. I. Antiandrogens and DNA synthesis. Invest Urol 11: 45–54: 1973PubMedGoogle Scholar
  58. 58.
    Trachtenberg J, Hicks LL, Walsh PC: Methods for the determination of androgen receptor content in human prostatic tissue. Invest Urol 18: 349–354, 1981PubMedGoogle Scholar
  59. 59.
    Walsh PC, Korenman SG: Mechanism of androgenic action—effect of specific intracellular inhibitors. J Urol 108: 116–119, 1972Google Scholar
  60. 60.
    Wendel EF, Brannen GE, Putong PB, Grayhack JT: The effect of orchidectomy and estrogens on benign prostatic hypertrophy. J Urol 108: 116–119, 1972PubMedGoogle Scholar
  61. 61.
    White JW: The results of double castration in hypertrophy of the prostate. Ann Surg 22: 1–80, 1895PubMedCrossRefGoogle Scholar
  62. 62.
    Woessner J: Collagenase in uterine resorption. In Woolley DE, Evanson JM (eds.): Collagenase in Normal and Pathological Connective Tissue. Wiley, Chichester, 1980, pp 223–239Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1983

Authors and Affiliations

  • Daniel P. de Klerk

There are no affiliations available

Personalised recommendations